SUNDAY, JUNE 24, 2018

Robin David Isaacs new chief medical officer at Entasis Therapeutics

Robin David Isaacs new chief medical officer at Entasis Therapeutics.
Robin David Isaacs new chief medical officer at Entasis Therapeutics. | Courtesy of
Entasis Therapeutics, a company that uses its expertise and unique pathogen-targeted approach for creating and advancing new antibacterials, recently announced that it has made Robin David Isaacs, M.D., its new chief medical officer.

“Dr. Isaacs’ experience in clinical research, global clinical development and life-cycle management of infectious disease products is extremely valuable as we approach significant milestones with our lead candidate, ETX0914, and advance our preclinical pipeline,” Manos Perros, Ph.D., president and CEO of Entasis, said. “The expertise that Dr. Isaacs brings complements the strengths of our management team, enhancing our efforts to deliver novel cures to patients who lack other treatment options.”

Isaacs brings his vast experience as a pharmaceutical executive to the creation and launch of infectious disease products and vaccines.

“With significant milestones ahead and the opportunity to develop meaningful new treatments, this is an exciting time to be joining Entasis,” Isaacs said. “ETX0914, which is a first-in-class novel oral antibiotic currently in Phase 2 for the treatment of uncomplicated gonorrhea, has been designated a Qualified Infectious Disease Product (QIDP) by the FDA and awarded Fast-Track status. I am thrilled to be a part of a team exploring new therapies in a directed, focused way to introduce medicines with improved efficacy for these very challenging pathogens.”

Organizations in this Story

Entasis Therapeutics

Want to get notified whenever we write about Entasis Therapeutics ?
Next time we write about Entasis Therapeutics, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.